

BioMed Israel 2025 ABSTRACT

Company name: Everly Bio

Website: www.everly.bio

CEO name: Michal Gilon Ohev-Zion

CATEGORY: Medical Devices

SESSION:

- Mind the Gap, Empowering Women's Health Through Data and Innovation

- **Executive Summary / Investment Rational**

Infertility affects 1 in 6 couples worldwide, with demand for fertility services at an all-time high. However, current solutions have limited predictive success. With a multidisciplinary team of REI, embryologist, scientists and computational experts, Everly Bio is transforming infertility treatments with a multi-system, non-invasive, AI-driven approach that enhances outcomes and accessibility.

- **Core Technology**

Everly Bio targets molecular markers for successful implantation in reproductive fluids. Unlike most solutions focusing on one aspect of the fertility journey, Everly Bio takes a holistic approach. While current methods rely on subjective morphology, Everly Bio provides molecular insights. Non-invasive, data-driven technology ensures safer diagnostics and personalized signatures enable tailored interventions for each couple.

- **Product Profile/Pipeline**

We have identified key decision points along the fertility journey where our solution can deliver the greatest impact — one of which is embryo selection, a critical factor for improving implantation rates. We've already established a strategic collaboration with the innovation arm of Israel's largest IVF center and have plans to expand our technology pipeline.

- **Business Strategy**

Our technology forms the foundation for a medical device that delivers rapid results. This device will be integrated with an app that continuously collects and analyzes clinical data, generating a report that can be shared with clinicians and, of course, prospective parents. Our solution aims to generate significant revenue by reducing unnecessary procedures, minimizing medication use, and enhancing overall efficiency.

- **What's Next?**

Everly Bio aims to advance biological processing for product development while enhancing our computational prediction model. We plan to conduct clinical trials in the U.S. and validation in Israel, expand regulatory efforts for FDA approval, and pursue a seed round to accelerate clinical validation and product prototyping, driving us toward a key inflection point.